Literature DB >> 19194534

Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study.

Mariusz Kruk1, Jacek Kadziela, Harmony R Reynolds, Sandra A Forman, Zygmunt Sadowski, Bruce A Barton, Daniel B Mark, Aldo P Maggioni, Jonathan Leor, John G Webb, Michael Kapeliovich, Jose A Marin-Neto, Harvey D White, Gervasio A Lamas, Judith S Hochman.   

Abstract

OBJECTIVES: This study sought to determine predictors of outcome and examine the influence of baseline risk on therapeutic impact of late mechanical opening of a persistently occluded infarct related artery after myocardial infarction in stable patients.
BACKGROUND: Previous studies in patients with acute coronary syndromes suggest that the impact of infarct-related artery recanalization on clinical outcome is greatest in patients at highest risk.
METHODS: Of 2,201 patients (age 58.6 +/- 11.0 years) with infarct-related artery occlusion on days 3 to 28 after myocardial infarction in the OAT (Occluded Artery Trial) study, 1,101 were assigned to percutaneous coronary intervention (PCI) and 1,100 to medical therapy alone and followed for a mean of 3.2 years. The primary end point was a composite of death, reinfarction, or New York Heart Association functional class IV heart failure. Interaction of treatment effect with tertiles of predicted survival were examined using the Cox survival model.
RESULTS: The 5-year rate for the primary end point was 18.9% versus 16.1% for patients assigned to PCI and medical treatment alone, respectively (hazard ratio [HR]: 1.14, 95% confidence interval [CI]: 0.92 to 1.43, p 0.23). Lack of benefit of PCI was consistent across the risk spectrum for both the primary end point and total mortality, including for the highest tertile (33.9% PCI vs. 27.3% medical treatment alone, HR: 1.27, 99% CI: 0.87 to 1.85 primary end point and 23.5% PCI vs. 21.7% medical treatment alone, HR: 1.16, 99% CI: 0.73 to 1.85 mortality). The independent predictors of the composite outcome were history of heart failure (HR: 2.06, p < 0.001), peripheral vascular disease (HR: 1.93, p 0.001), diabetes (HR: 1.49, p 0.002), rales (HR: 1.88, p < 0.001), decreasing ejection fraction (HR: 1.48 per 10%, p < 0.001), decreasing days from myocardial infarction to randomization (HR: 1.04 per day, p < 0.001), and decreasing glomerular filtration rate (HR: 1.11 per 10 ml/min/1.73 m(2), p < 0.001).
CONCLUSIONS: In the OAT study, there was no variation in the effect of PCI on clinical outcomes at different levels of patient risk, including the subset with very high event rates. (Occluded Artery Trial [OAT]; NCT00004562)

Entities:  

Keywords:  myocardial infarction; revascularization; risk factors; trials

Mesh:

Substances:

Year:  2008        PMID: 19194534      PMCID: PMC2635493          DOI: 10.1016/j.jcin.2008.08.007

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  25 in total

1.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

Authors:  Gregg W Stone; Cindy L Grines; David A Cox; Eulogio Garcia; James E Tcheng; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; John D Carroll; Barry D Rutherford; Alexandra J Lansky
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain.

Authors:  I Kallikazaros; C Tsioufis; S Sideris; C Stefanadis; P Toutouzas
Journal:  Stroke       Date:  1999-05       Impact factor: 7.914

3.  The underlying risk of death after myocardial infarction in the absence of treatment.

Authors:  Malcolm R Law; Hilary C Watt; Nicholas J Wald
Journal:  Arch Intern Med       Date:  2002-11-25

4.  TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.

Authors:  D A Morrow; E M Antman; A Charlesworth; R Cairns; S A Murphy; J A de Lemos; R P Giugliano; C H McCabe; E Braunwald
Journal:  Circulation       Date:  2000-10-24       Impact factor: 29.690

5.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

Authors:  E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

6.  Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization.

Authors:  John H Chiu; Eric J Topol; Patrick L Whitlow; Amy P Hsu; E Murat Tuzcu; Irving Franco; David J Moliterno
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

7.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.

Authors:  Frans Van de Werf; Diego Ardissino; Amadeo Betriu; Dennis V Cokkinos; Erling Falk; Keith A A Fox; Desmond Julian; Maria Lengyel; Franz-Josef Neumann; Witold Ruzyllo; Christian Thygesen; S Richard Underwood; Alec Vahanian; Freek W A Verheugt; William Wijns
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

9.  A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.

Authors:  Kim A Eagle; Michael J Lim; Omar H Dabbous; Karen S Pieper; Robert J Goldberg; Frans Van de Werf; Shaun G Goodman; Christopher B Granger; P Gabriel Steg; Joel M Gore; Andrzej Budaj; Alvaro Avezum; Marcus D Flather; Keith A A Fox
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Relationship of cardiac disease to stroke occurrence, recurrence, and mortality.

Authors:  J P Broderick; S J Phillips; W M O'Fallon; R L Frye; J P Whisnant
Journal:  Stroke       Date:  1992-09       Impact factor: 7.914

View more
  5 in total

1.  Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Authors:  Ramin S Hastings; Judith S Hochman; Vladimir Dzavik; Gervasio A Lamas; Sandra A Forman; Francois Schiele; Lampros K Michalis; Dimitris Nikas; Joanna Jaroch; Harmony R Reynolds
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

2.  Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT).

Authors:  Irene M Lang; Sandra A Forman; Aldo P Maggioni; Witold Ruzyllo; Jean Renkin; Carlos Vozzi; P Gabriel Steg; Jose-Maria Hernandez-Garcia; Krzysztof Zmudka; Manuel Jimenez-Navarro; George Sopko; Gervasio A Lamas; Judith S Hochman
Journal:  EuroIntervention       Date:  2009-11       Impact factor: 6.534

3.  Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial.

Authors:  Ph Gabriel Steg; Arthur Kerner; G B John Mancini; Harmony R Reynolds; Antonio C Carvalho; Viliam Fridrich; Harvey D White; Sandra A Forman; Gervasio A Lamas; Judith S Hochman; Christopher E Buller
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

4.  Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial.

Authors:  Venu Menon; Camille A Pearte; Christopher E Buller; Ph Gabriel Steg; Sandra A Forman; Harvey D White; Paolo N Marino; Demosthenes G Katritsis; Paulo Caramori; Ricardo Lasevitch; Krystyna Loboz-Grudzien; Aleksander Zurakowski; Gervasio A Lamas; Judith S Hochman
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

5.  Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).

Authors:  Mariusz Kruk; Christopher E Buller; James Enlou Tcheng; Vladimir Dzavík; Venugopal Menon; G B John Mancini; Sandra A Forman; Peter Kurray; Benita Busz-Papiez; Gervasio A Lamas; Judith S Hochman
Journal:  Am J Cardiol       Date:  2010-01-01       Impact factor: 2.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.